Emanuele Zucca, MD | Authors

22W451 BROKER RD

Articles

The Management of Nongastric MALT Lymphomas

January 15, 2014

No definite guidelines exist for the management of nongastric MALT lymphoma. Retrospective series have included patients treated with different modalities, and excellent cause-specific and overall survival have been demonstrated, independent of the type of treatment adopted.

Splenic Marginal Zone Lymphoma: Current Knowledge and Future Directions

February 15, 2012

In this article, we review the current knowledge on the biological findings, clinical features, and therapeutic approaches for splenic marginal zone lymphoma.

Nodal Marginal Zone B-Cell Lymphoma: A Diagnostic and Therapeutic Dilemma

January 17, 2012

The aim of this review is twofold: to summarize descriptions of the clinical presentation provided in published series in order to help clinicians recognize and treat patients, and to discuss diagnostic difficulties faced by hematopathologists when dealing with these lesions and others in the differential diagnosis that must be distinguished from one another.

MALT Lymphomas: Pathogenesis Can Drive Treatment

November 15, 2011

Marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT) lymphoma is an indolent B-cell non-Hodgkin lymphoma arising from the lymphoid tissue at extranodal sites.

Cutaneous T-Cell Lymphoma: From Genetics to Clinical Practice

February 01, 2007

This challenging supplement to ONCOLOGY is based on the proceedings of a closed expert symposium, and provides an overview of our current knowledge on primary cutaneous T-cell lymphomas (CTCL). The complete spectrum from genetics to clinical practice is covered.

Activity of Rituximab in Extranodal Marginal Zone Lymphomas (MALT Type)

March 01, 2002

This phase II study aimed to evaluate the tolerability and activity of the monoclonal anti-CD20 antibody rituximab (Rituxan) in patients with either untreated or relapsed biopsy-proven extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT) type, with measurable or evaluable disease.